Effect of denosumab vs zoledronic acid on bone turnover markers in postmenopausal women with severe osteoporosis
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2013
Price : $35 *
At a glance
- Drugs Denosumab (Primary) ; Zoledronic acid
- Indications Postmenopausal osteoporosis
- Focus Biomarker; Therapeutic Use
- 06 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
- 02 Nov 2012 New trial record
- 16 Oct 2012 Results presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.